After yesterday's sharp declines, today's Wall Street opening brings a slight recovery. The main spot indices are gaining 0.60-0.70%, and futures on these indices are rebounding by over 2.00% due to contract rollovers. The dollar is slightly weakening but remains significantly above yesterday's pre-FOMC conference levels. Meanwhile, U.S. bond yields continue to rise. The strong upward trend is particularly evident in 10-year yields, which are approaching 4.56%.
US500
The US500 index lost nearly 3.00% after yesterday's Federal Reserve decision, marking its biggest one-day loss since August this year following the release of NFP data. The chart shows a precarious ascending triangle technical pattern, which typically signals a trend reversal. Yesterday's strong breakout below the lower support line may potentially indicate such a scenario is materializing. If this is the case, continued selling pressure should be expected. On the other hand, bulls are making an effort to defend the support level above 5930 points.
Start investing today or test a free demo
Open real account TRY DEMO Download mobile app Download mobile app
Source: xStation 5
Company Highlights
Sangamo Therapeutics (SGMO.US): Shares gained 4.30% after licensing its STAC-BBB capsid technology to Astellas Pharma for $20M upfront, up to $1.3B in milestones, and royalties, targeting neurological diseases.
Accenture (ACN.US)ย gains 0.70% as FQ1 results beat expectations, FY2025 revenue growth outlook was raised to 4%-7%, and plans to return $8.3B to shareholders boosted confidence.
Micron Technology (MU.US)ย dips 15% due to weak FQ2 guidance, with earnings ($1.33โ$1.53/share) and revenue ($7.7Bโ$8.1B) below consensus, despite optimism for AI-driven growth.
Vertex Pharmaceuticals (VRTX.US)ย dropped 11.85% after trial results for its pain drug suzetrigine showed similar efficacy to placebo (-1.98 vs. -2.02), raising concerns despite plans for pivotal trials.
ย
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
